PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product under.....Equipment used in the production, processing, or packaging of a PET drug product should be appropriate for the.....Appropriate stability-indicating methods that can distinguish degradation products and impurities..
http://www.fda.gov/cder/guidance/4259dft.htm (score=100)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....discuss significant departures from the approaches outlined in this guidance with the..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=79)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....should explain the scientific reasons why a stability indicating procedure is not viable.....apply the content recommendations in this guidance, as scientifically appropriate, and/or..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=65)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....should explain the scientific reasons why a stability indicating procedure is not viable.....apply the content recommendations in this guidance, as scientifically appropriate, and/or..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=64)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...ensure that each batch of PET drug product meets its established acceptance criteria, 1201.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....errors and ensure that appropriate corrective action is taken to prevent their recurrence..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=55)

stability guidance -draft
...Significant change for a drug product at the accelerated stability condition and the.....appropriate for a drug product with respect to the likelihood that such a design would.....appropriate stability studies on batches of product, and submit the information in an..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=54)

Packaging
...It should provide an adequate seal, be compatible with the drug product, and not be a source of.....In these early stages, the IND should also indicate that appropriate stability studies with the.....It is also possible for a component of the drug product to migrate through the walls of the..
http://www.fda.gov/cder/guidance/package.htm (score=53)

Guidance for Industry
...ensuring that the drug product provided to the patient has the appropriate identity, strength.....provided that they meet appropriate standards or specifications as demonstrated by.....if the condition of the drug product, as a result of storage or shipping, casts doubt on the..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0165-gdl0001.pdf (score=52)

6003dft.doc
...changes and that no adverse impact on the quality, safety, or efficacy of the drug product.....therefore, real-time concurrent stability studies on the product potentially affected by.....identify the appropriate FDA staff, call the appropriate number listed on the title page..
http://www.fda.gov/cder/guidance/6003dft.pdf (score=51)

Draft Guidance: ICH Q5E: Comparability of Biotechnological/Biological...
...Therefore, it might be appropriate to collect data on the drug product to support the determination of comparability even though.....Generally, therefore, real-time concurrent stability studies on the product potentially.....Characterisation of a biotechnological/biological product by appropriate techniques, as described in..
http://www.fda.gov/cber/gdlns/ichcompbio.htm (score=49)

International Conference on Harmonisation; Draft Guidance on Q5E...
...changes and that no adverse impact on the quality, safety, or efficacy of the drug product.....therefore, real-time concurrent stability studies on the product potentially affected by.....identify the appropriate FDA staff, call the appropriate number listed on the title page..
http://www.fda.gov/cber/gdlns/ichcompbio.pdf (score=47)

HUMAN DRUG CGMP NOTES June 1966
...used in the delivery of a medical drug product is considered an integral part of the drug.....Where stability testing reveals that the BPC is stable for the intended period of use, or.....Once that level has been determined, firms may establish appropriate corresponding..
http://www.fda.gov/cder/hdn/hdn696.htm (score=47)

/a//content.14388
...Mixing, granulating, milling, molding, of components, drug product containers, formulating.....appropriate phases of manufacturing, appropriate controls over computer or.. clarify that.....whether they use terminal sterilization, three initial batches in the stability.. Sampling..
http://www.fda.gov/cder/dmpq/fr5396.pdf (score=46)

Q1B Photostability Testing of New Drug Substances and Products
...The extent of drug product testing should be established by assessing whether or not acceptable.....As a direct challenge for samples of solid drug substances, an appropriate amount of sample should be taken.....The ICH Harmonized Tripartite Guideline on Stability Testing of New Drug Substances and..
http://www.fda.gov/cder/guidance/1318.htm (score=44)

Substance
...individual batches of the drug substance used in animal and clinical testing, Drug.....relation to the amount of crude product, whether it is filtered while hot, whether a.....Precautions, including animal safety testing when appropriate, to detect, identify, and..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=44)

Content and Format of INDs for Phase 1 Studies of Drugs, Inclu
...with the appropriate division in the CDER Office of New Drug Chemistry,or the appropriate CBER division with.....used to monitor the stability of the drug product packaged in..the proposed container/closure system and storage.....manufacturing differences between the drug product proposed for..clinical use and the drug..
http://www.fda.gov/cder/guidance/clin2.pdf (score=43)

IND content and format for Phase 1 studies
...As clinical development of a drug product proceeds,sponsors should discuss the manufacturing.....the appropriate division in the CDER Office of New Drug Chemistry,or the appropriate CBER division with.....methods used to monitor the stability of the drug..product packaged in the proposed..
http://www.fda.gov/cder/guidance/phase1.pdf (score=43)

Guidance- Content & Format CMC for Vaccine & Related Product
...A list should be provided of all components in the drug product, including drug substance(s)and.....the evidence derived from validation studies which assures that product identity, purity, potency, and stability is preserved for.....appropriate quality and purity of the starting materials, including the seed organisms..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=41)

7356-002-Draft: DRUG MANUFACTURING INSPECTIONS (Pilot Program)
...The health significance of certain CGMP deviations may be lower when the drug product involved.....stability testing program, including demonstration of stability indicating capability of.....Such products should be given inspection coverage with appropriate priority.Inspections..
http://www.fda.gov/ora/cpgm/7356_002/7356-002-Draft.html (score=41)

HUMAN DRUG CGMP NOTES June 1998
...FOR EACH BATCH OF DRUG PRODUCT, there shall be appropriate laboratory determination of satisfactory conformance to.....Hence, sunscreen products must be labeled with an expiration date that is based on appropriate.....If that were true then there should never be any batch failures or drug product recalls, and we..
http://www.fda.gov/cder/hdn/cnotes68.htm (score=40)

Las Vegas Injury Lawyer